A PHASE I STUDY OF ORAL PANOBINOSTAT (LBH589) ALONE AND IN COMBINATION WITH DOCETAXEL (DOC) AND PREDNISONE IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC)

被引：0

作者：

Rathkopf, D. E. ^{[1
]}

Wong, B. Y. ^{[2
]}

Ross, R. W. ^{[3
]}

George, D. J. ^{[4
]}

Picus, J. ^{[5
]}

Atadja, P. ^{[6
]}

Yang, W. ^{[7
]}

Culver, K. W. ^{[7
]}

Woo, M. M. ^{[8
]}

Scher, H. I. ^{[9
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Div Solid Tumor Oncol, New York, NY 10021 USA

[2] Nevada Canc Inst, Dept Hematol Malignancies, Las Vegas, NV USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Duke Univ, Med Ctr, Dept Med & Surg, Durham, NC 27706 USA

[5] Washington Univ, Div Med Oncol, St Louis, MO USA

[6] Novartis Inst Biomed Res, Cambridge, MA USA

[7] Novartis Pharmaceut, Oncol Early Clin Dev, Florham Pk, NJ USA

[8] Novartis Oncol, Clin Pharmacol, Florham Pk, NJ USA

[9] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, New York, NY 10021 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：199 / 200

页数：2